1931 - 1940 of 8571 Results
Title
Year
- Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease (4418)2020RESTRICTEDTitle: Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease (4418)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.4418Citation Count: 0
- Patient-specific analysis of the relationship between the volume of tissue activated during DBS and verbal fluency2010OPENTitle: Patient-specific analysis of the relationship between the volume of tissue activated during DBS and verbal fluencyJournal Name: NeuroImagePublisher: Elsevier BVVol: 54Issue #:Start Page: S238End Page: S246Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuroimage.2010.03.068Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/2908727Citation Count: 111
-
RESTRICTEDTitle: Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson’s diseaseJournal Name: BrainPublisher: Oxford University Press (OUP)Vol: 147Issue #: 11Start Page: 3702End Page: 3713Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1093/brain/awae303Citation Count: 4
- BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides2025OPENTitle: BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating TriglyceridesJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 68Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1021/acs.jmedchem.4c03046Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c03046Citation Count: 4
-
OPENTitle: GDNF signaling in subjects with minimal motor deficits and Parkinson's diseaseJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 153Issue #:Start Page: 105298End Page: 105298Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.nbd.2021.105298Best OA location URL: https://doi.org/10.1016/j.nbd.2021.105298Citation Count: 24
- LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits2020OPENTitle: LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 12Issue #: 540Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.aav0820Best OA location URL: https://stm.sciencemag.org/content/scitransmed/12/540/eaav0820.full.pdfCitation Count: 108
- Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort2025RESTRICTEDTitle: Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohortJournal Name: eBioMedicinePublisher: Elsevier BVVol: 119Issue #:Start Page: 105866End Page: 105866Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ebiom.2025.105866Best OA location URL: https://www.thelancet.com/pdfs/journals/ebiom/PIIS2352-3964(25)00310-X.pdfCitation Count: 0
- Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers2016OPENTitle: Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 HeteromersJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 7Issue #: 9Start Page: 1201End Page: 1211Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.6b00036Best OA location URL: http://doi.org/10.1021/acschemneuro.6b00036Citation Count: 57
- Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson’s disease2025OPENTitle: Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson’s diseaseJournal Name: Cell ReportsPublisher: Elsevier BVVol: 44Issue #: 5Start Page: 115636End Page: 115636Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.celrep.2025.115636Best OA location URL: https://doi.org/10.1016/j.celrep.2025.115636Citation Count: 0
- Developing better digital health measures of Parkinson’s disease using free living data and a crowdsourced data analysis challenge2023OPENTitle: Developing better digital health measures of Parkinson’s disease using free living data and a crowdsourced data analysis challengeJournal Name: PLOS Digital HealthPublisher: Public Library of Science (PLoS)Vol: 2Issue #: 3Start Page: e0000208End Page: e0000208Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1371/journal.pdig.0000208Best OA location URL: https://journals.plos.org/digitalhealth/article/file?id=10.1371/journal.pdig.0000208&type=printableCitation Count: 5